Castle Biosciences to Present at the Baird 2018 Global Healthcare Conference

On August 30, 2018 Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, reported that Derek Maetzold, President and CEO, will present at the Baird Global Healthcare Conference on Wednesday, September 5th, 2018 at 11:25 a.m. ET in New York City (Press release, Castle Biosciences, AUG 30, 2018, View Source [SID1234529198]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Array BioPharma to Present at the Wells Fargo Securities 2018 Healthcare Conference

On August 30, 2018 Array BioPharma Inc. (Nasdaq: ARRY) reported that its Chief Executive Officer, Ron Squarer, will speak at the Wells Fargo Securities 2018 Healthcare Conference in Boston (Press release, Array BioPharma, AUG 30, 2018, View Source [SID1234529222]). The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:

Wells Fargo Securities 2018 Healthcare Conference

Presenter:

Ron Squarer, Chief Executive Officer, Array BioPharma

Date:

Thursday, September 6, 2018

Time:

3:05 p.m. Eastern Time

Webcast:

https://cc.talkpoint.com/well001/090518a_as/?entity=47_0GHY12N

Eureka Therapeutics to Present Proof-of-Concept Preliminary Data from Ongoing China Clinical Study of ET140202 at CAR-TCR 2018 Summit

On August 30, 2018 Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, reported that new proof-of-concept preliminary data from its ongoing China clinical study evaluating ET140202 for the treatment of AFP-positive hepatocellular carcinoma (AFP+ HCC) will be presented as a late-breaking oral presentation at the 4th Annual CAR-TCR Summit in Boston, Massachusetts, September 4-7, 2018 (Press release, Eureka Therapeutics, AUG 30, 2018, View Source [SID1234529199]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation details are listed below and are accessible on the 4th Annual CAR-TCR Summit website:

Presentation Title: Case Report of Regression of Metastatic Liver Cancer After ET140202 T-Cell Therapy
Session Title: Late Breaking Abstracts
Date & Time: Wednesday, September 5, 2018 from 9:15 a.m. – 9:35 a.m. ET
Location: Seaport Hotel & World Trade Center

Presentation Title: Improvement of Safety in T-cell Immunotherapies for the Treatment of Cancer
Session Title: Overcoming CAR-T Toxicity in Solid Tumors (Agenda 1)
Date & Time: Friday, September 7, 2018 from 1:00 p.m. – 1:30 p.m. ET
Location: Seaport Hotel & World Trade Center

Heat Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City

On August 29, 2018 Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, reported it will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, Heat Biologics, AUG 29, 2018, https://heatbio.com/heat-biologics-present-20th-annual-rodman-renshaw-global-investment-conference-new-york-city/ [SID1234529241]). The conference is being held on September 4-6, 2018 at The St. Regis New York in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jeff Wolf, Founder and Chief Executive Officer of Heat Biologics, will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event: 20th Annual Rodman & Renshaw Global Investment Conference

Date: Wednesday, September 5, 2018

Time: 4:40-5:05 PM (Eastern Time)

Location: Louis XVI B; The St. Regis New York

If you are unable to attend and would like to view the Company’s live webcast, please click on the following link (View Source).

Loxo Oncology to Present at Upcoming Investor Conferences

On August 29, 2018 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, reported that company management will participate in fireside chats at the following upcoming investor conferences (Press release, Loxo Oncology, AUG 29, 2018, View Source [SID1234529124]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi Annual Biotech Conference in Boston on September 5, 2018 at 8:45 a.m. ET

Morgan Stanley Global Healthcare Conference in New York City on September 13, 2018 at 9:10 a.m. ET

Live webcasts of the fireside chats will be available at View Source